Regulatory product record
GALLIPRANT
Product identity, ingredients and source provenance from the regulatory catalogue. Linked clinical evidence has a separate review status.
Product identity
- Brand name
- GALLIPRANT
- DIN
- 02484269
- DPD drug code
- 97458
- Regulatory category
- APPROVED_VET_DRUG
- Market status
- MARKETED
- Route(s)
- ORAL
- Pharmaceutical form(s)
- TABLET
- Ingredients
- GRAPIPRANT (60 MG)
- Species (DPD record)
- DOGS
- Company
- ELANCO CANADA LIMITED (DIN owner)
Source and provenance
- Source dataset
- health_canada_dpd_marketed
- Source snapshot date
- Not available in this source
- Source record key
- 97458
- Archive fingerprint (SHA-256)
- 85cc3ce208af3aa57018c3d14d83f90220c436baef7455384b6d48d9774e1c88
Linked clinical reference
Clinical entries are linked through the active molecule. Check their species, formulation, source and review status separately from this product record.
Clinical evidence
Dose regimens0
No dose regimens recorded for this species selection.
Adverse effects141
These are counts of spontaneously reported events, not proven adverse effects, causal relationships, or incidence rates.
Bars compare report counts within each species; they do not show incidence.
More reportsFewer reportsDog
- Vomiting1,425 reports
- Diarrhoea1,256 reports
- Lack of efficacy - NOS958 reports
- Lethargy (see also Central nervous system depression in 'Neurological')659 reports
- Elevated alanine aminotransferase (ALT)508 reports
- Death by euthanasia476 reports
- Not eating466 reports
- Decreased appetite428 reports
- Bloody diarrhoea392 reports
- Weight loss347 reports
- Elevated blood urea nitrogen (BUN)340 reports
- Elevated serum alkaline phosphatase (SAP)317 reports
Cat
- Elevated blood urea nitrogen (BUN)4 reports
- Hiding4 reports
- Death by euthanasia3 reports
- Elevated creatinine3 reports
- Lack of efficacy - NOS3 reports
- Vomiting3 reports
- Weight loss3 reports
- Decreased activity2 reports
- Decreased appetite2 reports
- Not eating2 reports
- Accidental exposure1 reports
- Agitation1 reports
Literature references18
References are linked to this drug. Species applicability is not recorded here, so the species filter does not narrow this list. Imported dates do not retain their original precision; confirm dates in the original citation.
- Evaluation of clinical effects and plasma metabolomic profiles after the administration of grapiprant in dogs affected by osteoarthritis: a prospective, off-on-off, clinical study.
Study summary not available in the imported record. Open the original citation to review the study.
- Assessment of safety profile and analgesia provided by grapiprant and metamizole alone or combined for postoperative analgesia of queens undergoing elective ovariohysterectomy.
Study summary not available in the imported record. Open the original citation to review the study.
- Does grapiprant reduce osteoarthritic pain in dogs?
Study summary not available in the imported record. Open the original citation to review the study.
- Efficacy of combined grapiprant and tapentadol for analgesia in cats undergoing elective ovariohysterectomy.
Study summary not available in the imported record. Open the original citation to review the study.
- Targeting the mPGES-PGE(2)-EP4 pathway with MF63, MK886, and Grapiprant as a potential therapeutic strategy for Escherichia coli-induced endometritis in dairy cows.
Study summary not available in the imported record. Open the original citation to review the study.
Sources: PubMed, National Library of Medicine; openFDA, U.S. Food and Drug Administration.